Latest Breaking News On - மருத்துவ சாதனங்கள் நிறுவனம் - Page 1 : comparemela.com
Fixed Ophthalmic Examination System Market Business Growth 2021-2026: Johnson & Johnson , CSO ,Delta Electronics , Echo-Son , iVis Technologies – KSU
ksusentinel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ksusentinel.com Daily Mail and Mail on Sunday newspapers.
Apr 5, 2021
Speaking on the occasion Shri DV Sadananda Gowda commended India’s capabilities as a global and reliable supplier of drugs and medical devices during the COVID-19 pandemic. Citing the recent UNCTAD report, he also pointed out India’s positive FDI growth even with a decline in FDI of 42% globally. Shri Gowda said, “As the pandemic exposed the global vulnerabilities of the supply chains in the pharmaceuticals sector, the Department of Pharmaceuticals launched the Production Linked Incentive Scheme for bulk drugs, with a financial outlay of ₹6,940 crores across 53 APIs over 6 years. For Medical Devices, another PLI scheme was announced with an outlay of ₹3,420. Such interventions & incentives have played an instrumental role in realizing Prime Minister’s vision of ‘Aatmanirbhar Bharat’, or India for the world.”
Govt allocates PLI scheme of Rs 6,940 Cr for bulk drugs & Rs 3,420 Cr for medical devices
Govt allocates PLI scheme of Rs 6,940 Cr for bulk drugs & Rs 3,420 Cr for medical devices
25 February 2021 | News Fulfilling the vision of Aatmanirbhar Bharat, the government has allocated over Rs. 10,000 crores in PLI scheme for bulk drugs and medical devices: DV Sadananda Gowda
Speaking at the inauguration ceremony of India Pharma 2021 & India Medical Devices 2021 organised by FICCI along with the Department of Pharmaceuticals, Ministry of Chemicals & Fertilisers, Government of India, and Invest India, DV Sadananda Gowda, Minister for Chemicals and Fertilisers, Government of India said, “ The Department of Pharmaceuticals launched the Production Linked Incentive Scheme for bulk drugs, with a financial outlay of Rs 6,940 crore across 53 APIs over six years. For medical devices, another PLI scheme was announced with an outlay of Rs 3,420 crore. The medical devices industry in I
Medical devices company, TransEnterix (NYSEARCA:TRXC) is another small-cap growth stock that has sprung back to life in 2020. TRXC stock is up a whopping 1322% in the past six months. The company’s robotics platform will likely get significant traction this year, as regulatory approvals will support growth opportunities. The goal is for its “Senhance” robotics technology to gain widespread clinical adoption in the laparoscopic field. A few risks remain, though, and its inflated price limits TRXC stock’s attractiveness. Source: Shutterstock TransEnterix’s Senhance platform essentially reduces variability in surgical procedures and thus improves patient outcomes for laparoscopic procedures. The platform’s initial sales were encouraging but quickly dropped off, as it failed to meet physician expectations. However, the company has worked incredibly hard to fix its teething issues and invested in extensors such as its Intelligent Surgical Unit. FDA
Zimmer Biomet Holdings on Feb. 5 announced the spin-off of its spine and dental businesses into a new and independent publicly-traded company. The medical devices company expects the move to contribute 50 basis points to revenue growth over a five-year period. It is anticipated to be 125 basis points accretive to EBITDA and operating margins. The spin-off is also forecasted to accelerate Zimmer Biomet’s EPS growth on a pro forma basis. Zimmer Biomet (ZBH) plans to close the transaction in the middle of next year. This spinoff is expected to tap into a $21 billion combined market for spine and dental devices like dental implants and motion preservation devices. Zimmer Biomet CEO Bryan Hanson said, “As part of the third phase of ZB’s ongoing transformation, we are changing the complexion of our business through active portfolio management in order to accelerate growth and drive value creation. For Zimmer Biomet, the transaction is an important step toward shifting ou
vimarsana © 2020. All Rights Reserved.